Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
an educational grant from
Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company
of Johnson & Johnson
Description:
Pulmonary Arterial Hypertension (PAH) is a progressive vascular
disorder characterized by vascular remodeling of the pulmonary
arteries which carry blood from the heart to the lungs. For those
with PAH, the muscles within the arterial walls tighten, which often
leads to a progressive increase in pulmonary vascular resistance
that leads to right ventricular failure and significant morbidity
and mortality. Over time, the heart muscle can become so weakened
that its ability to pump enough blood through the body is lost,
leading to heart failure. About half of people diagnosed with PAH
will not live past five years, while those with untreated PAH have
an average survival expectancy of approximately three years
following diagnosis. There continue to be significant challenges in
identifying and diagnosing PAH because it requires a combination of
information based on symptoms, a physician examination, risk
factors, and other findings based on previous tests. Evaluation
typically include laboratory testing, echocardiography, pulmonary
function testing, assessment of exercise capacity with six-minute
walk distance or cardiopulmonary exercising testing, imaging, and a
right heart catheterization among others.
The American College of Chest Physicians (ACCP) also published new
treatment guidelines in 2019. There are a wide variety of treatment
options to help manage PAH, including general measures, nonspecific
pharmacologic intervention and targeted pharmacologic intervention.
These include monotherapy and combination therapies that can include
prostacyclin/prostacyclin analogues, endothelin receptor
antagonists, and phosphodiesterase-5 inhibitors. Physicians must be
able to make tailored treatment decisions for individual patients,
based on their diagnosis and severity, for proper management.
Optimal treatment, accurate classification, and risk stratification
are keys to managing the patient’s health and costs, as incorrect
classification can lead to inappropriate treatment decisions. The
current guidance recommendations suggest that the optimal
therapeutic approach for each patient must be personalized to take
into account a patient’s severity, route of administration of
therapy, adverse effect profiles, comorbidity, and achieving
treatment goals. As such, patients require access to all indicated
treatment options to optimize disease management.
Upon completion of this
activity, participants will be able to:
-
Review the latest clinical evidence
and guidelines for the best management of pulmonary arterial
hypertension (PAH)
-
Discuss signs and symptoms of PAH to
identify best practices for achieving an early and accurate
diagnosis
-
Examine clinical data to show the
safety and efficacy of treatments for PAH, including the use and
effectiveness of combination therapies
-
Explore goal-directed strategies to
effectively manage treatment, adherence, and adverse events
-
Assess effective management
strategies for a patient-centered, multidisciplinary approach to
care for and improve the quality of life in patients with PAH
|
Faculty: |
Steven Nathan, MD
Medical Director, Advanced Lung Disease and Transplant
Program
Inova Fairfax Hospital
Professor of Medicine, Virginia Commonwealth University |
|
Disclosure:
|
Dr. Nathan
serves on the speaker’s bureau for Boerhinger-Ingelheim,
Roche-Genentech, and Bayer. He serves as a consultant
for Bayer, Boerhinger-Ingelheim, Bellephoron, Galapagos,
Promedior, Roche, United Therapeutics, Third Pole,
Altavant. He has received research funding from Bayer,
Boerhinger-Ingelheim, and United Therapeutics. His
presentation has been peer-reviewed for any bias. |
|
|
Planning Committee:
Bill Williams,
MD has no real or perceived financial relationships to
disclose.
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is supported by an educational grant from
Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company
of Johnson & Johnson
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |